PLUR

Pluri Inc

Add to Watchlist

Advanced Chart

5.156

+0.046(0.900%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.310

Open

5.310

VWAP

5.12

Vol

2.80K

Mkt Cap

40.58M

Low

5.120

Amount

14.37K

EV/EBITDA(TTM)

Total Shares

5.39M

44.22M

EV/OCF(TTM)

P/S(TTM)

28.92

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.

1 Analyst Rating

132.74% Upside

Wall Street analysts forecast PLUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PLUR is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

132.74% Upside

Current: 5.156

Low

12.00

Averages

12.00

High

12.00

132.74% Upside

Current: 5.156

Low

12.00

Averages

12.00

High

12.00

Alliance Global Partners

Matthew Venezia

initiated

$12

2025-06-02

Reason

Alliance Global Partners

Matthew Venezia

Price Target

$12

2025-06-02

initiated

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Pluri Inc (PLUR.O) is -1.85, compared to its 5-year average forward P/E of -1.66. For a more detailed relative valuation and DCF analysis to assess Pluri Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.66

Current PE

-1.85

Overvalued PE

0.43

Undervalued PE

-3.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2.65

Current PS

17.26

Overvalued PS

11.06

Undervalued PS

-5.76

Financials

Annual

Quarterly

FY2025Q3

YoY :

+501.41%

427.00K

Total Revenue

FY2025Q3

YoY :

-2.42%

-5.40M

Operating Profit

FY2025Q3

YoY :

+17.53%

-6.34M

Net Income after Tax

FY2025Q3

YoY :

+9300.00%

-0.94

EPS - Diluted

FY2025Q3

YoY :

+13.73%

-4.88M

Free Cash Flow

FY2025Q3

YoY :

-68.15%

31.85

Gross Profit Margin - %

FY2025Q3

YoY :

-64.70%

-1.76K

FCF Margin - %

FY2025Q3

YoY :

-80.46%

-1.48K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

4.5M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

4.5M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

PLUR News & Events

Events Timeline

2025-05-27 (ET)

2025-05-27

07:05:48

BrainStorm signs LOI with Minaris to manufacture NurOwn

2025-05-15 (ET)

2025-05-15

07:16:53

Pluri CEO issues letter to shareholders

2025-04-28 (ET)

2025-04-28

08:22:26

Pluri completes strategic acquisition of 71% of equity of Kokomodo for $4.5M

News

7.5

05-27Newsfilter

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

4.5

05-15Newsfilter

Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion

3.5

04-10Newsfilter

Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel